

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934

For the month of February 2013.

Commission File Number: 001-34949

---

**Tekmira Pharmaceuticals**

*(Translation of registrant's name into English)*

**100-8900 Glenlyon Parkway  
Burnaby, British Columbia  
Canada, V5J 5J8**

*(Address of principal executive office)*

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [  ] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**DOCUMENTS FILED AS PART OF THIS FORM 6-K**

See the Exhibit Index hereto.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Tekmira Pharmaceuticals**

Date: February 6, 2013

By: /s/ IAN C. MORTIMER

Name: Ian C. Mortimer

Title: *Executive Vice President, Finance and Chief Financial Officer*

---

**EXHIBIT INDEX**

<u>Exhibit</u>	<u>Description</u>
99.1	Press release dated February 6, 2013

## **Tekmira to Webcast Presentation at 15th Annual BIO CEO & Investor Conference**

VANCOUVER, British Columbia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that management will present a company overview at the 15<sup>th</sup> Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 10:30 am ET (7:30 am PT) at the Waldorf Astoria Hotel in New York, NY.

A live webcast of the presentation can be accessed through the Investor section of Tekmira's website at [www.tekmirapharm.com](http://www.tekmirapharm.com). An archived webcast will be available on the Tekmira website for 90 days following the event.

### **About Tekmira**

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at [www.tekmirapharm.com](http://www.tekmirapharm.com). Tekmira is based in Vancouver, B.C.

The Tekmira Pharmaceuticals logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=8319>

#### **CONTACT: Investors**

Jodi Regts  
Director, Investor Relations  
Phone: 604-419-3234  
Email: [jregts@tekmirapharm.com](mailto:jregts@tekmirapharm.com)

#### **Media**

David Ryan  
Longview Communications Inc.  
Phone: 416-649-8007  
Email: [dryan@longviewcomms.ca](mailto:dryan@longviewcomms.ca)